氢溴酸卤夫酮（Halofuginone hydrobromid，代号RU-19110）是常山碱（Febrifugine）的衍生物，作为竞争性脯氨酰-tRNA合成酶抑制剂（Ki=18.3nM），兼具多重生物活性与作用机制——可特异性抑制I型胶原合成、通过抑制TGF-β活性减轻骨关节炎，还能激活Kv通道并阻断电压门控、受体操作及存储操作型Ca²⁺通道而发挥肺血管扩张作用，同时具有抗疟疾、抗炎、抗癌及抗纤维化功效。

[1] Tsuchida K, Tsujita T, Hayashi M, Ojima A, Keleku-Lukwete N, Katsuoka F, Otsuki A, Kikuchi H, Oshima Y, Suzuki M, Yamamoto M. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radic Biol Med. 2017 Feb;103:236-247. doi: 10.1016/j.freeradbiomed.2016.12.041. Epub 2016 Dec 28. PMID: 28039084.[2]Jain PP, Zhao T, Xiong M, Song S, Lai N, Zheng Q, Chen J, Carr SG, Babicheva A, Izadi A, Rodriguez M, Rahimi S, Balistrieri F, Rahimi S, Simonson T, Valdez-Jasso D, Thistlethwaite PA, Shyy JY, Wang J, Makino A, Yuan JX. Halofuginone, a promising drug for treatment of pulmonary hypertension. Br J Pharmacol. 2021 Sep;178(17):3373-3394. doi: 10.1111/bph.15442. Epub 2021 Jul 31. PMID: 33694155; PMCID: PMC9792225.